Literature DB >> 8337851

Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein.

W I Cox1, J Tartaglia, E Paoletti.   

Abstract

Successful immunization against many viruses, including retroviruses such as HIV-1, is thought to depend upon the roles of both antibody and cytotoxic T-lymphocyte responses. With safety a major concern, we developed two poxvirus recombinants expressing the envelope glycoprotein of HIV-1 IIIB. Canarypox (ALVaC), which is not known to replicate in mammalian cells, and a highly attenuated vaccinia (NYVAC) virus deleted of 18 open reading frames associated with virulence and host range were used as vectors. Upon inoculation into BALB/c mice, both the ALVAC and NYVAC recombinants were capable of inducing antibody responses to HIV gp120 and provoking remarkable levels of primary and memory Thy1.2+, CD4-, CD8+ cytotoxic T-lymphocyte responses to the hypervariable V3 loop of the HIV-1 envelope glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8337851     DOI: 10.1006/viro.1993.1442

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

Review 1.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

2.  Role of cell signaling in poxvirus-mediated foreign gene expression in mammalian cells.

Authors:  Ningjie Hu; Richard Yu; Cecilia Shikuma; Bruce Shiramizu; Mario A Ostrwoski; Qigui Yu
Journal:  Vaccine       Date:  2009-03-10       Impact factor: 3.641

3.  DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice.

Authors:  Preeti Pancholi; Marion Perkus; Nancy Tricoche; Qingyan Liu; Alfred M Prince
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

Review 4.  Applications of pox virus vectors to vaccination: an update.

Authors:  E Paoletti
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

5.  Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria.

Authors:  D E Lanar; J A Tine; C de Taisne; M C Seguin; W I Cox; J P Winslow; L A Ware; E B Kauffman; D Gordon; W R Ballou; E Paoletti; J C Sadoff
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

6.  Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus.

Authors:  K H Leong; A J Ramsay; D B Boyle; I A Ramshaw
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  Highly attenuated poxviruses induce functional priming of neutrophils in vitro.

Authors:  R Förster; G Wolf; A Mayr
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

8.  Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors.

Authors:  Xiugen Zhang; Farah Cassis-Ghavami; Mike Eller; Jeff Currier; Bonnie M Slike; Xuemin Chen; James Tartaglia; Mary Marovich; Paul Spearman
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

9.  NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

Authors:  J A Tine; D E Lanar; D M Smith; B T Wellde; P Schultheiss; L A Ware; E B Kauffman; R A Wirtz; C De Taisne; G S Hui; S P Chang; P Church; M R Hollingdale; D C Kaslow; S Hoffman; K P Guito; W R Ballou; J C Sadoff; E Paoletti
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

10.  CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals.

Authors:  Jun Liu; Qigui Yu; Geoffrey W Stone; Feng Yun Yue; Nicholas Ngai; R Brad Jones; Richard S Kornbluth; Mario A Ostrowski
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.